Abrdn Life Sciences Investors Stock

Equities

HQL

US87911K1007

Closed End Funds

Market Closed - Nyse 04:00:02 2024-04-22 pm EDT 5-day change 1st Jan Change
12.99 USD +1.48% Intraday chart for Abrdn Life Sciences Investors +0.12% -3.49%
Sales 2021 2.29M Sales 2022 3.02M Capitalization 343M
Net income 2021 64M Net income 2022 -105M EV / Sales 2021 225 x
Net Debt 2021 10.04M Net Debt 2022 11.09M EV / Sales 2022 117 x
P/E ratio 2021
7.95 x
P/E ratio 2022
-3.35 x
Employees -
Yield 2021
8.03%
Yield 2022
10.8%
Free-Float 97.83%
More Fundamentals * Assessed data
Dynamic Chart
Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing MT
Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund and Tekla Healthcare Investors Approves Election of Rose Dimartino, C. William Maher, Todd Reit and Stephen Bird as New Trustees CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 29, 2023 CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2023 CI
Tekla Life Sciences Investors Declares Distribution, Payable on June 30, 2023 CI
Tekla Life Sciences Investors announces an Equity Buyback for 12% of its outstanding shares. CI
Tekla Life Sciences Investors authorizes a Buyback Plan. CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2023 CI
Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Tekla Life Sciences Investors Declares Distribution, Payable on December 30, 2022 CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 30, 2022 CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2022 CI
Tekla Life Sciences Cuts Quarterly Dividend to $0.35 a Share From $0.39, Payable June 30 to Shareholders as of May 27 MT
Tekla Life Sciences Investors Declares a Distribution, Payable on June 30, 2022 CI
Sector Update: Financial Stocks Adding to Tuesday Gains Just Ahead of Closing Bell MT
More news
1 day+1.48%
1 week+0.12%
Current month-4.70%
1 month-4.13%
3 months-6.75%
6 months+10.27%
Current year-3.49%
More quotes
1 week
12.76
Extreme 12.76
13.01
1 month
12.76
Extreme 12.76
13.71
Current year
12.76
Extreme 12.76
14.37
1 year
11.34
Extreme 11.34
14.37
3 years
11.34
Extreme 11.34
22.70
5 years
11.34
Extreme 11.34
22.70
10 years
11.34
Extreme 11.34
31.21
More quotes
Managers TitleAgeSince
President 71 00-12-31
Chief Tech/Sci/R&D Officer - -
Compliance Officer 56 08-12-31
Members of the board TitleAgeSince
Director/Board Member 74 06-12-31
President 71 00-12-31
Director/Board Member 62 19-12-31
More insiders
Date Price Change Volume
24-04-22 12.99 +1.48% 73,176
24-04-19 12.8 +0.08% 94,479
24-04-18 12.79 0.00% 148,012
24-04-17 12.79 -0.23% 77,666
24-04-16 12.82 -1.19% 84,052

Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT

More quotes
abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.
More about the company